Alkem Laboratories Limited (ALKEM)

Loading page…

Alkem Laboratories Limited (ALKEM) · mywealthgrid

About

Alkem Laboratories operates in pharmaceuticals within Healthcare sector. Market cap ₹64,201 Cr, with ROE 17.84% and operating margin 20.43% indicating mid-cap scale and solid profitability.

Founded: 1973
Face value: ₹2

Market cap

₹62,431 Cr

P/E

28.9×

P/B

4.5×

Dividend yield

1.2%

ROE

17.8%

ROCE

21.5%

Debt / equity

0.12

OPM

20.4%

EPS (TTM)

₹180.5

Book value

₹1,156.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margins swing from 30.32% (Sep 2025) to 15.23% (Mar 2026), indicating significant quarterly volatility; verify drivers.
PE 29.76 is elevated; verify if earnings growth can sustain this valuation.
Promoter shareholding fell from 51.2% (Mar 2026) to 49.7% (Jun 2026) in single quarter; verify intent and impact.
D/E ratio 0.12 is very low; verify if conservative approach or underutilized financial capacity.

Generated analysis · source review pending

Growth drivers

Consolidated revenue ₹3,600–4,000 Cr in recent quarters; verify if this scale is growing year-on-year and sustainable.
Operating margin peaked 30.32% (Sep 2025) at consolidated revenue ₹4,000.99 Cr; verify if high margins replicable at this scale or product-specific.
Net profit ranged ₹217–786 Cr across recent quarters; verify if quarterly volatility represents seasonal patterns or indicates uneven performance.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹5,220.0-0.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 18.6% (3-yr avg)
+High return on capital employed of 21.1%
+Healthy operating margin of 20.4%
+Comfortable interest coverage of 19.9×
+Dividend payout of 33.8% of profit

Cons

−Promoter holding fell 3.3 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

56/100

Business quality: 70
Growth: 47
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 150 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET NIFTY HEALTHCARE INDEX

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6,431	7,357	8,344	8,865	10,634	11,599	12,668	12,965	14,712
COGS	2,513	2,945	3,345	3,498	4,180	4,907	4,938	4,764	5,093
Gross profit	3,918	4,412	4,999	5,367	6,454	6,692	7,730	8,200	9,620
	2,890	3,297	3,526	3,424	4,401	5,083	5,485	5,689	6,616
	1,028	1,115	1,473	1,942	2,053	1,609	2,245	2,512	3,003
OPM %	16%	15.2%	17.7%	21.9%	19.3%	13.9%	17.7%	19.4%	20.4%
Depreciation	143	193	253	275	304	310	299	357	382
Interest	55	55	65	59	52	107	112	122	161
	96	88	104	233	148	113	189	494	409
Profit before tax	926	955	1,260	1,842	1,844	1,305	2,023	2,526	2,869
Tax	288	181	110	224	164	298	212	311	518
Tax %	31.1%	19%	8.8%	12.2%	8.9%	22.8%	10.5%	12.3%	18.1%
	638	774	1,149	1,618	1,680	1,007	1,811	2,215	2,351
PAT margin %	9.9%	10.5%	13.8%	18.3%	15.8%	8.7%	14.3%	17.1%	16%
EPS (₹)	52.8	63.6	94.3	132.6	137.6	82.3	150.2	181.1	192.5
EPS adjusted (₹)	52.8	63.6	94.3	135.3	137.7	82.3	150.2	181.1	192.5
	24.6%	25.2%	26.5%	22.6%	42.9%	30.4%	26.6%	24.8%	27.5%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	24	24	24	24	24	24	24	24	24	24	24
Reserves	3,095	4,444	4,840	5,415	—	7,353	8,614	9,021	10,288	11,961	13,796
Minority interest	85	115	122	133	—	181	209	390	402	449	529
	1,183	654	892	903	—	1,701	2,580	1,397	1,214	1,063	1,624
	952	1,331	1,788	1,734	—	2,261	2,642	2,925	3,647	4,195	4,901
Total equity & liabilities	5,339	6,568	7,666	8,208	—	11,519	14,069	13,757	15,575	17,691	20,873
	1,034	1,452	1,938	2,173	2,908	2,793	2,902	2,683	2,873	2,852	3,871
CWIP	112	299	381	493	—	393	339	310	148	477	138
Investments	497	553	444	324	—	333	371	622	484	1,846	1,869
	3,696	4,264	4,902	5,219	—	8,000	10,457	10,142	12,070	12,517	14,995
Total assets	5,339	6,568	7,666	8,208	—	11,519	14,069	13,757	15,575	17,691	20,873

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	60%	59.9%	60.5%	60.7%	57.7%	61%	63.3%	65.4%
EBITDA margin %	15.2%	17.7%	21.9%	19.3%	13.9%	17.7%	19.4%	20.4%
EBIT margin %	12.5%	14.6%	18.8%	16.4%	11.2%	15.4%	16.6%	17.8%
PAT margin %	10.5%	13.8%	18.3%	15.8%	8.7%	14.3%	17.1%	16%
Working capital
Receivable days	62	—	66	65	67	65	69	74
Inventory days	186	—	241	262	194	197	224	239
Payable days	—	—	112	102	87	129	141	161
NWC days	—	—	196	225	174	132	152	152
Leverage
Current ratio	1.9	—	1.92	1.76	2.32	2.61	2.73	2.55
Debt to EBITDA	0.81	—	0.88	1.26	0.87	0.54	0.42	0.54
Debt to equity	0.17	—	0.23	0.3	0.15	0.12	0.09	0.12
Interest coverage	18.5	20.4	32.3	36.5	14.1	20.1	21.8	19.9
Asset turnover	0.9	—	0.77	0.76	0.84	0.81	0.73	0.7
Return ratios
Return on assets %	9.4%	—	14%	11.9%	7.3%	11.6%	12.5%	11.3%
Return on capital employed %	17.9%	—	24%	22.3%	15.7%	20.9%	20.9%	21.5%
Return on equity %	14.2%	—	21.9%	19.5%	11.1%	17.6%	18.5%	17%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	56.74%	56.74%	56.74%	56.38%	55.66%	55.66%	55.13%	53.04%	51.2%	51.2%	51.2%	49.7%
	6.03%	8.49%	9.11%	8.69%	9.02%	10.15%	9.41%	9.11%	9.48%	9.97%	10.16%	10.42%
	17.64%	15.91%	15.63%	18.57%	19.21%	18.01%	19.42%	21.8%	21.93%	21.54%	21.4%	22.63%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	19.59%	18.86%	18.52%	16.36%	16.11%	16.18%	16.04%	16.05%	17.39%	17.29%	17.24%	17.25%
No. of shareholders	—	—	—	—	—	—	—	—	67,196	64,536	62,835	62,822

Promoter holding down 7.04 percentage points since Sep 2023.

54 deals · 25 Jan 2024 – 2 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
2 Jun 2026	JAYANTI SINHA	Bulk	NSE	Sell	12,38,220	₹5,200.00	₹643.87 Cr
2 Jun 2026	JAYANTI SINHA	Block	NSE	Sell	12,38,220	₹5,200.00	₹643.87 Cr
2 Jun 2026	ICICI PRUDENTIAL MUTUAL FUND	Block	NSE	Buy	9,03,527	₹5,200.00	₹469.83 Cr
2 Jun 2026	ICICI PRUDENTIAL MUTUAL FUND	Bulk	NSE	Buy	9,03,527	₹5,200.00	₹469.83 Cr
2 Jun 2026	SAMPRADA&NANHAMATI SINGH FAMILY TRUST	Block	NSE	Sell	5,50,000	₹5,200.00	₹286.00 Cr
2 Jun 2026	HDFC MUTUAL FUND	Block	NSE	Buy	5,09,615	₹5,200.00	₹265.00 Cr
2 Jun 2026	DSP MUTUAL FUND	Block	NSE	Buy	86,538	₹5,200.00	₹45.00 Cr
2 Jun 2026	GOLDMAN SACHS BANK EUROPE SE	Block	NSE	Buy	48,090	₹5,200.00	₹25.01 Cr
2 Jun 2026	NIPPON INDIA MUTUAL FUND	Block	NSE	Buy	48,090	₹5,200.00	₹25.01 Cr
2 Jun 2026	SOCIETE GENERALE	Block	NSE	Buy	48,090	₹5,200.00	₹25.01 Cr

1–10 of 54

1 / 6

Mr. Basudeo N. SinghExecutive Director-Chairperson
Mr. Sandeep SinghExecutive Director-MD
Mr. Mritunjay Kumar SinghExecutive Director
Mrs. Madhurima SinghExecutive Director
Mr. Sarvesh SinghExecutive Director
Mr. Srinivas SinghExecutive Director
Mr. Narendra AnejaNon-Executive - Independent Director
Mr. Sujjain TalwarNon-Executive - Independent Director
Mr. Rajeev KherNon-Executive - Independent Director
Mr. Laxmana Ranjal ShenoyNon-Executive - Independent Director
Mrs. Neela BhattacherjeeNon-Executive - Independent Director

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹5,163.0 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹5,171.5	-152.5	-2.9%	₹5,171.5	15,034	+32	1,292	125
23 Nov 2026	₹5,199.0	-149	-2.8%	₹5,199.0	55	+9	33	125
29 Dec 2026	₹5,246.0	-82.5	-1.5%	₹5,244.5	1	+1	1	125

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

36

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
0	0	0	₹0.0	4,300

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 16 fund houses

Held by these funds

8.2%

of the company's equity

All mutual funds

16.71%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

92 schemes · 16 fund houses

		Shares
Large and Midcap Fund	SBI Mutual Fund	14.77 L	787.01	1.86%	1.235%	-0
Growth Mid Cap FundNEW	Nippon India Mutual Fund	12.3 L	655.74	1.25%	1.029%	—
Midcap Fund	Axis Mutual Fund	8.92 L	475.41	1.34%	0.746%	-0
Focused FundNEW	ICICI Prudential Mutual Fund	6.61 L	352.24	1.96%	0.553%	—
Large & Mid Cap Fund	DSP Mutual Fund	6.52 L	347.36	1.89%	0.545%	+85,350
Mid Cap Fund	DSP Mutual Fund	6.45 L	343.77	1.64%	0.539%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	6.4 L	340.98	4.87%	0.535%	—
Aggressive Hybrid Fund	DSP Mutual Fund	4.01 L	213.91	1.82%	0.336%	+55,240

1–8 of 92

1 / 12

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

32 announcementsExport CSV

20 Aug 2026, 6:01 pmCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	60%	59.9%	60.5%	60.7%	57.7%	61%	63.3%	65.4%
EBITDA margin %	15.2%	17.7%	21.9%	19.3%	13.9%	17.7%	19.4%	20.4%
EBIT margin %	12.5%	14.6%	18.8%	16.4%	11.2%	15.4%	16.6%	17.8%
PAT margin %	10.5%	13.8%	18.3%	15.8%	8.7%	14.3%	17.1%	16%
Working capital
Receivable days	62	—	66	65	67	65	69	74
Inventory days	186	—	241	262	194	197	224	239
Payable days	—	—	112	102	87	129	141	161
NWC days	—	—	196	225	174	132	152	152
Leverage
Current ratio	1.9	—	1.92	1.76	2.32	2.61	2.73	2.55
Debt to EBITDA	0.81	—	0.88	1.26	0.87	0.54	0.42	0.54
Debt to equity	0.17	—	0.23	0.3	0.15	0.12	0.09	0.12
Interest coverage	18.5	20.4	32.3	36.5	14.1	20.1	21.8	19.9
Asset turnover	0.9	—	0.77	0.76	0.84	0.81	0.73	0.7
Return ratios
Return on assets %	9.4%	—	14%	11.9%	7.3%	11.6%	12.5%	11.3%
Return on capital employed %	17.9%	—	24%	22.3%	15.7%	20.9%	20.9%	21.5%
Return on equity %	14.2%	—	21.9%	19.5%	11.1%	17.6%	18.5%	17%

Calls	Strike	Puts
0	0	0	₹0.0	4,300

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
20 Aug 2026, 6:01 pm	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
20 Aug 2026, 6:00 pm	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
17 Aug 2026, 7:02 pm	AGM/EGM Court Convened Meeting	Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting	PDF
15 Aug 2026, 5:08 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
14 Aug 2026, 7:14 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
14 Aug 2026, 2:00 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
14 Aug 2026, 1:57 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF
14 Aug 2026, 1:55 pm	Company Update General	Announcement Under Reg 30 (LODR)	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	726	471	266	780	585	1,265	1,111	1,683	1,948	1,913	1,963
	202	-286	-357	-316	-741	-999	-1,435	113	-1,009	-1,299	-1,667
	-927	-138	85	-379	79	-272	380	-1,761	-1,145	-811	-503
Net cash flow	—	—	—	—	—	-5	55	35	-205	-197	-208
Free cash flow	726	471	266	780	585	1,070	772	1,450	1,689	1,237	1,346
CFO / Operating profit %	—	—	25.9%	69.9%	39.7%	65.1%	54.1%	104.5%	86.8%	76.1%	65.3%

Alkem Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

3

36

Fund holders

Documents

Announcements

Events

Announcements

3

36

Announcements

Annual reports

Investor Presentation and earnings call

22

1

Compounded sales growth

Compounded profit growth

Return on equity

Alkem Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Futures3

Option chain36

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Futures3

Option chain36

Announcements

Annual reports

Investor Presentation and earnings call

Dividends22

Board meetings1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

36

3

36

22

1